|
Level 2, 369 Royal Parade Parkville, Victoria 3052, Australia Tel. +61-3-9349-4906 Fax +61-3-9348-0377 |
Type: Public
On the web:
http://www.pranabio.com
Employees:
9
Employee growth: (25.0%)
Prana Biotechnology wants to give Alzheimer's disease a prize fight. The biotechnology company is developing therapies for age-related degenerative conditions, including Alzheimer's. Targeting the proteins that build on the brains of Alzheimer's patients, Prana Biotechnology is developing drug candidates to treat the memory-sapping disease. The company aims to develop therapies for other neurological disorders including Parkinson's disease, Huntington's disease, and macular degeneration. Prana, founded in 1997, partners with other pharmaceutical and biotechnology companies.
Key numbers for fiscal year ending June, 2011:
Sales: $0.2M
One year growth: (10.1%)
Net income: ($6.8)M
Officers:
Chairman and CEO: Geoffrey P. Kempler
COO: Dianne Angus
CFO and Secretary: Richard Revelins
Competitors:
Hoffmann-La Roche
Johnson & Johnson
Pfizer
A profitability measure that looks at a company's profits before the company has to pay corporate income tax. This measure deducts all expenses from revenue including interest expenses and operating expenses, but it leaves out the payment of tax.
Also referred to as "earnings before tax ".
Investopedia Says:
This measure combines all of the company's profits before tax, including operating, non-operating, continuing operations and non-continuing operations. PBT exists because tax expense is constantly changing and taking it out helps to give an investor a good idea of changes in a company's profits or earnings from year to year.
Related Links:
Learn this easy-to-understand technique of analyzing a company's financial statements and reports. Introduction To Fundamental Analysis
Investors need to know the varieties of EPS and what each represents to really determine whether a company is a good value.
Investors Beware: There Are 5 Types Of Earnings Per Share
Halted. Market Data powered by QuoteMedia, fundamentals by Morningstar. Terms of use.
Read more